Published on
October 20, 2025
- 12:33 GMT
Reconnect Labs Reaches Key Milestone in Phase 2 Study of RE03 for PTSD-Related Sleep Disturbances
First patient enrolled in Phase 2 trial evaluating RE03, a novel therapeutic targeting sleep disturbances associated with post-traumatic stress disorder (PTSD) ZURICH, SWITZERLAND, October 20, 2025 /EINPresswire.com/ -- We’re proud to announce that the …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
